Lourdes Cecilia Correa González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lourdes Cecilia Correa González has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Edgar Alejandro Turrubiartes-Martínez
Medical Genomics Section, Research Center in Health Sciences and Biomedicine, Universidad Autónoma de San Luis Potosí, San Luis Potosi 78210, Mexico
1 shared publication - Eduardo Roberto Caballero Lugo
Hospital Regional de Alta Especialidad “Dr. Ignacio Morones Prieto”, San Luis Potosi 78290, Mexico
1 shared publication - Esther Layseca-Espinosa
Molecular and Translational Medicine Section, Research Center for Health Sciences and Biomedicine, Universidad Autónoma de San Luis Potosí, San Luis Potosi 78210, Mexico
1 shared publication - Gabriel Mata-Moreno
Medical Genomics Section, Research Center in Health Sciences and Biomedicine, Universidad Autónoma de San Luis Potosí, San Luis Potosi 78210, Mexico
1 shared publication - Perla Niño-Moreno
Center of Research in Health Sciences and Biomedicine, Faculty of Medicine, Autonomous University of San Luis Potosi, San Luis Potosi 78210, Mexico
1 shared publication - Óscar Pérez Ramírez
Hospital Regional de Alta Especialidad “Dr. Ignacio Morones Prieto”, San Luis Potosi 78290, Mexico
1 shared publication
Latest Publications
- Open Access
Long Non-Coding RNA Expression in B-Cell Precursor Acute Lymphoblastic Leukemia: Analysis of LINC-PINT, MEG3, BALR6, and ZEB1-AS1
Background/Objectives: Long non-coding RNAs (lncRNAs) have been identified as potential biomarkers for cancer diagnosis and prognosis. In the present study, we proposed the analysis of four lncRNAs as a diagnostic support candidate for the follow-up of leukemia patients. The aim of this study was to characterize the expression of BALR6, LINC-PINT, MEG3, and ZEB1-AS1 in patients with B-cell acute lymphoblastic leukemia (B-ALL) at diagnosis and at the end of remission induction therapy. Methods: B-ALL diagnosis and MRD assessment were performed by flow cytometry, while lncRNA expression levels were quantified using TaqMan probe-based assays. Results: Fifteen pediatric patients with B-ALL were followed longitudinally. MRD evaluation identified seven refractory and eight remitted patients. Significant expression changes were observed for MEG3 in remitted patients and for BALR6 and LINC-PINT in refractory patients. No statistically significant differences were detected for ZEB1-AS1. Conclusions: Changes in MEG3, LINC-PINT, and BALR6 lncRNA expression are associated with treatment response and MRD status in pediatric B-ALL, supporting their potential role as complementary biomarkers to conventional MRD monitoring.
Open AccessLong Non-Coding RNA Expression in B-Cell Precursor Acute Lymphoblastic Leukemia: Analysis of LINC-PINT, MEG3, BALR6, and ZEB1-AS1
Background/Objectives: Long non-coding RNAs (lncRNAs) have been identified as potential biomarkers for cancer diagnosis and prognosis. In the present study, we proposed the analysis of four lncRNAs as a diagnostic support candidate for the follow-up of leukemia patients. The aim of this study was to characterize the expression of BALR6, LINC-PINT, MEG3, and ZEB1-AS1 in patients with B-cell acute lymphoblastic leukemia (B-ALL) at diagnosis and at the end of remission induction therapy. Methods: B-ALL diagnosis and MRD assessment were performed by flow cytometry, while lncRNA expression levels were quantified using TaqMan probe-based assays. Results: Fifteen pediatric patients with B-ALL were followed longitudinally. MRD evaluation identified seven refractory and eight remitted patients. Significant expression changes were observed for MEG3 in remitted patients and for BALR6 and LINC-PINT in refractory patients. No statistically significant differences were detected for ZEB1-AS1. Conclusions: Changes in MEG3, LINC-PINT, and BALR6 lncRNA expression are associated with treatment response and MRD status in pediatric B-ALL, supporting their potential role as complementary biomarkers to conventional MRD monitoring.